Comparison 10. Subgroup analysis ‐ heparinised cell solution.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All‐cause mortality (< 12 months)	16		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 Heparin	6	339	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.31, 2.66]
1.2 No heparin	10	999	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.30, 1.45]
2 All‐cause mortality (≥ 12 months)	12		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Heparin	7	503	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.33, 2.10]
2.2 No heparin	5	408	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.28, 1.08]
3 LVEF measured by MRI (< 12 months)	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 Heparin	7	434	Mean Difference (IV, Random, 95% CI)	1.99 [‐0.62, 4.59]
3.2 No heparin	8	701	Mean Difference (IV, Random, 95% CI)	0.25 [‐1.67, 2.17]
4 LVEF measured by MRI (≥ 12 months)	9		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 Heparin	5	357	Mean Difference (IV, Random, 95% CI)	1.76 [‐1.93, 5.45]
4.2 No heparin	4	361	Mean Difference (IV, Random, 95% CI)	0.53 [‐2.14, 3.20]
5 LVEF measured by left ventricular angiography (< 12 months)	8		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 Heparin	5	256	Mean Difference (IV, Random, 95% CI)	6.82 [0.25, 13.39]
5.2 No heparin	3	393	Mean Difference (IV, Random, 95% CI)	1.91 [‐3.46, 7.27]